Fact CheckerSign in

NCT07627620Not yet recruitingPhase 2

Camrelizumab Combined With Famitinib Malate and Chemotherapy for Treatment of Recurrent/ Metastatic Cervical Cancer

A Multi-Center Phase II Clinical Study of Camrelizumab Combined With Famitinib Malate and Platinum-based Chemotherapy in the Treatment of Recurrent/Metastatic Cervical Cancer

Source: ClinicalTrials.gov · Last updated 4 Jun 2026

Brief summary (registry, in English)

This study is an open-label, multi-center Phase II clinical study, aimed to evaluate the efficacy and safety of camrelizumab combined with famitinib malate and platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer.

Status (registry)
Not yet recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
54 (estimated)
First submitted
31 May 2026
Start date
30 Jun 2026
Primary completion date
30 Sept 2027
Lead sponsor
Hunan Cancer Hospital
NCT number
NCT07627620

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 54
  • From 30 Jun 2026 to the primary completion date, 30 Sept 2027
  • No sites listed in no country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Has any malignancy \<5 years prior to study entry.
  • Received live vaccinations 4 weeks before randomization or during the study period.
  • Known allergies and contraindications to the investigational drug or any of its components.

Other illness

  • Known to have autoimmune disease.

Other

  • Known to have brain or meningeal metastasis.

Who the study is looking for

  • Female aged 18-75 years.
  • Histopathologically confirmed recurrent/metastatic cervical squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma that cannot be radically treated by surgery, radiotherapy or chemoradiotherapy.
  • No prior systemic anti-cancer therapy for recurrent/metastatic disease.
  • According to RECIST v1.1 criteria, the patient must have at least one measurable lesion.
  • Able to normally swallow drug tablets
  • Has adequate organ function.
  • Willing to participate and able to comply with research programme requirements.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  • Estimated life expectancy of more than 3 months.

Age in the registry: 18 years to 75 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

This page is information, not medical advice. Discuss any trial with your doctor.